Compare Deckers Outdoor Corp (DECK) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs Novavax Inc — how do they compare? Deckers Outdoor Corp trades at $82.95 (market cap $11.24B), while Novavax Inc trades at $11.1 (market cap $1.82B). The key difference: Deckers Outdoor Corp is far larger — about 6.2× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Deckers Outdoor Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Deckers Outdoor Corp for 71 Days and Novavax Inc for 59 Days on average.
| DECK | NVAX | |
|---|---|---|
Market Cap | $11.24B | $1.82B |
Volume | 3,010,945 | 6,198,505 |
Sector | Consumer Cyclical | Health |
52-Week High | $120.94 | $12.56 |
52-Week Low | $77.51 | $6.22 |
Typical Hold Time | 71 Days | 59 Days |
Enterprise Value | $10.11B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DECK trades at $80.38, down 1.57% on the day, with a neutral technical signal and strong fundamentals. Revenue grew to $4.99B in 2025, net income reached $966.09M, and profitability metrics like ROE of 42.56% are robust. Recent earnings beats and analyst upgrades reflect optimism, while cash flow trends show operational strength despite a projected net outflow in 2026.
The outlook is positive given valuation discounts (P/E 11.74), consistent earnings outperformance, and bullish analyst targets averaging $117.13. Risks include reliance on key brands HOKA and UGG, competitive pressures, and potential macroeconomic headwinds affecting consumer discretionary spending.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
